kdasales.blogg.se - Download hilum of lung

Methods: We conducted the prospective study of NSCLC patients treated by neoadjuvant Toripalimab (240mg, every 3 weeks) plus double platinum-based chemotherapy from December 2020 to March 2022 at Peking University Cancer Hospital. Here we elucidated the early onset of irAEs associated with better clinical outcomes in a prospective study (Renaissance study). Immune-related adverse events (irAEs) have been preliminarily implicated their association with treatment efficacy.

Beijing Cancer Hospital, Peking University, Beijing, Chinaīackground: Neoadjuvant immunotherapy with anti-PD-1 was proved promising in resectable non-small cell lung cancer (NSCLC).

Ye Tao, Xiang Li, Bing Liu, Jia Wang, Chao Lv, Shaolei Li, Yuzhao Wang, Jinfeng Chen, Shi Yan * and Nan Wu *